New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism

doi:10.12114/j.issn.1007-9572.2021.00.600

Abstract

Abstract: Venous thromboembolism（VTE）is a common complication，and the second leading non-cancer cause of death in cancer patients. Lymphoma is a type of cancer with a high incidence of VTE. However，there is no consensus on the risk factors and prevention methods for lymphoma-associated VTE. To provide the latest guidance on the prevention and treatment of lymphoma-associated VTE，in reviewing the recent guidelines and literature，we overviewed the influencing factors of lymphoma-associated VTE，including types and treatment of lymphoma，clinical laboratory indicators and anti-tumor therapies. Besides that，we also summarized and analyzed the recently developed risk prediction models for lymphoma-associated VTE，including the Khorana Risk Score，Ottawa Score，Michigan Risk Score and ThroLy Lymphoma Score.

Key words: Lymphoma, Venous thromboembolism, Influence factors, Prognostic model, Review

摘要： 静脉血栓（VTE）是恶性肿瘤的常见并发症，亦是导致肿瘤患者死亡的第二位非肿瘤致死因素。淋巴瘤是VTE发病率较高的肿瘤之一，然而，目前针对淋巴瘤相关VTE风险的危险因素以及防治方法尚未达到一致共识。因此，本文将结合最新指南及文献总结，将淋巴瘤相关VTE的影响因素及预测模型作一综述，分别介绍与淋巴瘤疾病本身、临床检验指标以及抗肿瘤治疗相关的VTE危险因素。同时，将4种VTE预测模型（即：Khorana评分、Ottawa评分、Michigan评分以及ThroLy评分）对淋巴瘤VTE风险的预测价值进行分析，为淋巴瘤相关VTE的防治提供新的指导。

关键词: 淋巴瘤, 静脉血栓, 影响因素, 预后模型, 综述

YANG Jingshi,ZOU Liqun. New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism　[J]. Chinese General Practice, 2021, 24(23): 2992-2997. DOI: 10.12114/j.issn.1007-9572.2021.00.600.
杨婧诗,邹立群. 淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展[J]. 中国全科医学, 2021, 24(23): 2992-2997. DOI: 10.12114/j.issn.1007-9572.2021.00.600.

References

［1］TIMP J F，BRAEKKAN S K，VERSTEEG H H，et al. Epidemiology of cancer-associated venous thrombosis［J］. Blood，2013，122（10）：1712-1723. DOI：10.1182/blood-2013-04-460121.
［2］KHORANA A A，KUDERER N M，CULAKOVA E，et al. Development and validation of a predictive model for chemotherapy-associated thrombosis［J］. Blood，2008，111（10）：4902-4907. DOI：10.1182/blood-2007-10-116327.
［3］ANTIC D，MILIC N，NIKOLOVSKI S，et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients［J］. Am J Hematol，2016，91（10）：1014-1019. DOI：10.1002/ajh.24466.
［4］YOKOYAMA K. Thrombosis in lymphoma patients and in myeloma patients［J］. Keio J Med，2015，64（3）：37-43. DOI：10.2302/kjm.2014-0017-RE.
［5］KEKRE N，CONNORS J M. Venous thromboembolism incidence in hematologic malignancies［J］. Blood Rev，2019，33：24-32. DOI：10.1016/j.blre.2018.06.002.
［6］GOLDSCHMIDT N，LINETSKY E，SHALOM E，et al. High incidence of thromboembolism in patients with central nervous system lymphoma［J］. Cancer，2003，98（6）：1239-1242. DOI：10.1002/cncr.11623.
［7］BYUN J M，HONG J，YOON S S，et al. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy［J］. Thromb Res，2019，183：131-135. DOI：10.1016/j.thromres.2019.10.002.
［8］ZHOU X，TEEGALA S，HUEN A，et al. Incidence and risk factors of venous thromboembolic events in lymphoma［J］. Am J Med，2010，123（10）：935-941. DOI：10.1016/j.amjmed.2010.05.021.
［9］FARGE D，BOUNAMEAUX H，BRENNER B，et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer［J］. Lancet Oncol，2016，17（10）：e452-466. DOI：10.1016/S1470-2045（16）30369-2.
［10］AY C，VORMITTAG R，DUNKLER D，et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer：results from the Vienna Cancer and Thrombosis Study［J］. J Clin Oncol，2009，27（25）：4124-4129. DOI：10.1200/JCO.2008.21.7752.
［11］LEKOVIC D，MILJIC P，MIHALJEVIC B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma［J］. Thromb Res，2010，126（6）：477-480. DOI：10.1016/j.thromres.2010.08.017.
［12］SAMUELSON BANNOW B T，KONKLE B A. Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies：a review［J］. Thromb Res，2018，163：138-145. DOI：10.1016/j.thromres.2018.01.037.
［13］NEGAARD H F S，IVERSEN P O，?STENSTAD B，et al. Hypercoagulability in patients with haematological neoplasia：no apparent initiation by tissue factor［J］. Thromb Haemost，2008，99（6）：1040-1048. DOI：10.1160/TH07-09-0541.
［14］RUPA-MATYSEK J，GIL L，BARANSKA M，et al. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma［J］. Oncotarget，2018，9（30）：21190-21200. DOI：10.18632/oncotarget.25002.
［15］RUPA-MATYSEK J，GIL L，KROLL-BALCERZAK R，et al. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma［J］. Hematol Oncol，2017，35（4）：456-464. DOI：10.1002/hon.2321.
［16］RIEDL J，KAIDER A，REITTER E M，et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study（CATS）［J］. Thromb Haemost，2014，111（4）：670-678. DOI：10.1160/TH13-07-0603.
［17］YILDIZ A，ALBAYRAK M，PALA ?，et al. The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients：a 9-year single-center experience ［J］. J Oncol Pharm Pract，2020，26（2）：386-396. DOI：10.1177/1078155219851540.
［18］LI J S，TIAN X D，WANG M J，et al. A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis［J］. Onco Targets Ther，2018，11：9007-9011. DOI：10.2147/OTT.S183298.
［19］PARK H，KIM J W，YOUK J，et al. Serum free light chain difference and β2 microglobulin levels are risk factors for thromboembolic events in patients with AL amyloidosis［J］. Clin Lymphoma Myeloma Leuk，2018，18（6）：408-414. DOI：10.1016/j.clml.2018.03.005.
［20］RUPA-MATYSEK J，GIL L，KAZMIERCZAK M，et al. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies：validation of the Khorana Risk Score［J］. Med Oncol，2017，35（1）：5. DOI：10.1007/s12032-017-1065-4.
［21］JACCARD A，GACHARD N，MARIN B，et al. Efficacy of L-asparaginase with methotrexate and dexamethasone（AspaMetDex regimen）in patients with refractory or relapsing extranodal NK/T-cell lymphoma，a phase 2 study［J］. Blood，2011，117（6）：1834-1839. DOI：10.1182/blood-2010-09-307454.
［22］DE STEFANO V，ZA T，CIMINELLO A，et al. Haemostatic alterations induced by treatment with asparaginases and clinical consequences［J］. Thromb Haemost，2015，113（2）：247-261. DOI：10.1160/TH14-04-0372.
［23］LEE J H，LEE J，YHIM H Y，et al. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea［J］. J Thromb Haemost，2017，15（4）：655-661. DOI：10.1111/jth.13636.
［24］SANFILIPPO K M，WANG T F，GAGE B F，et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma［J］. Thromb Res，2016，143：86-90. DOI：10.1016/j.thromres.2016.05.008.
［25］ZANGARI M，SIEGEL E，BARLOGIE B，et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide：implications for therapy［J］. Blood，2002，100（4）：1168-1171. DOI：10.1182/blood-2002-01-0335.
［26］PAREDES N，XU L，BERRY L R，et al. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces［J］. Br J Haematol，2003，120（2）：315-324. DOI：10.1046/j.1365-2141.2003.03971.x.
［27］DAVID R J，BARAN A，LOH K P，et al. Complications associated with dose-adjusted EPOCH-rituximab therapy for non-Hodgkin lymphoma［J］. Clin Lymphoma Myeloma Leuk，2018，18（12）：781-787. DOI：10.1016/j.clml.2018.08.014.
［28］ARORA M，GOWDA S，TUSCANO J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma［J］. Ther Adv Hematol，2016，7（4）：209-221. DOI：10.1177/2040620716652861.
［29］NOWAKOWSKI G S，LAPLANT B，MACON W R，et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma：a phase Ⅱstudy［J］. J Clin Oncol，2015，33（3）：251-257. DOI：10.1200/JCO.2014.55.5714.
［30］ALBERTSSON-LINDBLAD A，KOLSTAD A，LAURELL A，et al.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma［J］. Blood，2016，128（14）：1814-1820. DOI：10.1182/blood-2016-03-704023.
［31］NOWAKOWSKI G S，LAPLANT B，HABERMANN T M，et al. Lenalidomide can be safely combined with R-CHOP（R2CHOP）in the initial chemotherapy for aggressive B-cell lymphomas：phase I study［J］. Leukemia，2011，25（12）：1877-1881. DOI：10.1038/leu.2011.165.
［32］PAL R，MONAGHAN S A，HASSETT A C，et al. Immunomodulatory derivatives induce PU. 1 down-regulation，myeloid maturation arrest，and neutropenia［J］. Blood，2010，115（3）：605-614. DOI：10.1182/blood-2009-05-221077.
［33］YAMSHON S，CHRISTOS P J，DEMETRES M，et al. Venous thromboembolism in patients with B-cell non-hodgkin lymphoma treated with lenalidomide：a systematic review and meta-analysis［J］. Blood Adv，2018，2（12）：1429-1438. DOI：10.1182/bloodadvances.2018016683.
［34］KEY N S，KHORANA A A，KUDERER N M，et al. Venous thromboembolism prophylaxis and treatment in patients with cancer：ASCO clinical practice guideline update［J］. J Clin Oncol，2020，38（5）：496-520. DOI：10.1200/JCO.19.01461.
［35］SANTI RM，CECCARELLI M，BERNOCCO E，et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi（FIL）［J］. Thromb Haemost，2017，10.1160/TH16-11-0895. DOI：10.1160/TH16-11-0895.
［36］HOHAUS S，TISI M C，BARTOLOMEI F，et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization［J］. Blood Cancer J，2018，8（6）：54. DOI：10.1038/s41408-018-0096-1.
［37］LOUZADA M L，CARRIER M，LAZO-LANGNER A，et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism［J］. Circulation，2012，126（4）：448-454. DOI：10.1161/CIRCULATIONAHA.111.051920.
［38］DEN EXTER P L，KOOIMAN J，HUISMAN M V. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis［J］. J Thromb Haemost，2013，11（5）：998-1000. DOI：10.1111/jth.12192.
［39］ALATRI A，MAZZOLAI L，FONT C，et al. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry［J］. Thromb Haemost，2017，117（8）：1630-1636. DOI：10.1160/TH17-02-0116.
［40］CHOPRA V，KAATZ S，CONLON A，et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis［J］. J Thromb Haemost，2017，15（10）：1951-1962. DOI：10.1111/jth.13794.
［41］LUND J L，?STG?RD L S，PRANDONI P，et al. Incidence，determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark［J］. Thromb Res，2015，136（5）：917-923. DOI：10.1016/j.thromres.2015.09.001.
［42］JASTI N，STREIFF M B. Prevention and treatment of thrombosis associated with central venous catheters in cancer patients［J］. Expert Rev Hematol，2014，7（5）：599-616. DOI：10.1586/17474086.2014.954541.
［43］RUPA-MATYSEK J，BRZEZNIAKIEWICZ-JANUS K，GIL L，et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice ［J］. Cancer Med，2018，7（7）：2868-2875. DOI：10.1002/cam4.1540.
［44］KHORANA A A，FRANCIS C W，CULAKOVA E，et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy ［J］. J Thromb Haemost，2007，5（3）：632–634. DOI：10.1111/j.1538-7836.2007.02374.x.
［45］MAHAJAN A，BRUNSON A，WHITE R，et al. The epidemiology of cancer-associated venous thromboembolism：an update［J］. Semin Thromb Hemost，2019，45（4）：321-325. DOI：10.1055/s-0039-1688494.

[1]	HE Yang, YANG Rong, SHEN Can, YI Shanye, LIU Lidi, ZHAO Qian, WAN Zhi, LIAO Xiaoyang. Progress in Research on the Trajectory of Frailty and Its Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4372-4378.
[2]	ZHAO Jiayi, FAN Jian, YU Dehua. The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry [J]. Chinese General Practice, 2026, 29(30): 4366-4371.
[3]	LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479.
[4]	CHEN Yujing, WANG Yan, LI Guang, DONG Benchao, YANG Peichuan, MA Jianxiong. Digital Technologies in the Management of Sarcopenia among Older Adults in Asia: a Scoping Review [J]. Chinese General Practice, 2026, 29(29): 4200-4210.
[5]	XIE Xiaoyun, LIU Chenxi, LIU Yushu, ZHOU Yihan. Artificial Intelligence Research Practices in Primary Healthcare Institutions in China and the Potential Issue of Data Poverty: a Scoping Review [J]. Chinese General Practice, 2026, 29(28): 4067-4077.
[6]	FENG Yachen, LIU Lewei, XUE Jinyue, SUN Xianlin, LIU Huanzhong. Research Progress of Wearable Technology in the Diagnosis and Treatment of Mental Disorders [J]. Chinese General Practice, 2026, 29(27): 4016-4025.
[7]	LIU Yahui, XU Yanan, YUAN Ling, WU Ligui, ZHOU Yujie, KANG Yubiao. A Scoping Review on Triage for Palliative Care Patients Based on Priority Decision-making [J]. Chinese General Practice, 2026, 29(24): 3538-3544.
[8]	WANG Rui, LUO Shuoming, YANG Liang, WANG Peng, ZHAO Yang, WANG Qi, ZHOU Zhiguang. Diabetes Prevalence among Older Adults in China: a Systematic Review and Meta-analysis [J]. Chinese General Practice, 2026, 29(24): 3500-3508.
[9]	WU Liyun, SUN Huajing, GU Yiqing, MEI Ziqi, JIN Shengji, ZHANG Suju, ZHU Yun, ZHANG Yao, LI Qin, LIU Xiaomiao, WANG Qing, BAI Yamei, XU Guihua. Application of Digital-intelligent Technology in Electrocardiographic Monitoring for Acute Myocardial Infarction: a Scoping Review [J]. Chinese General Practice, 2026, 29(24): 3545-3552.
[10]	WU Ermei, SUN Dajuan, DENG Hualiang. A Review of Role of miRNA in Ulcerative Colitis and Traditional Chinese Medicine Intervention [J]. Chinese General Practice, 2026, 29(23): 3371-3378.
[11]	WANG Longyu, LI Ya, MA Qian, JIA Peilin, ZHANG Hailong. Clinical Application Progress of Diffusing Capacity of the Lung for Carbon Monoxide in Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2026, 29(23): 3379-3384.
[12]	RUAN Hejing, ZHAO Wen, LI Longcan, ZHAO Jiufa, LI Dongdong. The Non-canonical Functions and Therapeutic Prospects of Parkin in Metabolic Associated Fatty Liver Disease [J]. Chinese General Practice, 2026, 29(23): 3268-3274.
[13]	FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063.
[14]	LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949.
[15]	CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807.